Jae S. Yang

SNU Research Park
Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy.

Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy.

Journal: NPJ vaccines

Published: November 11, 2025

Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.

Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 22, 2025

Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.

Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.

Journal: Vaccine

Published: May 08, 2025

Mouse strain-dependent neutralizing antibody responses to Zika virus vaccines.

Mouse strain-dependent neutralizing antibody responses to Zika virus vaccines.

Journal: Journal of microbiology (Seoul, Korea)

Published: April 04, 2025

Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein.

Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein.

Journal: Scientific reports

Published: March 17, 2025

Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study.

Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study.

Journal: Vaccine

Published: March 07, 2025

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults.

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults.

Journal: mSphere

Published: December 26, 2024

Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine.

Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine.

Journal: Vaccine

Published: October 18, 2024

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity.

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity.

Journal: Tropical diseases, travel medicine and vaccines

Published: August 07, 2023

Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal.

Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal.

Journal: Human vaccines & immunotherapeutics

Published: August 04, 2023

Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.

Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.

Journal: The Lancet. Global health

Published: July 05, 2023

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.

Journal: The Lancet regional health. Western Pacific

Published: June 06, 2022

Showing 1-12 of 54

Last Updated: 09/26/2026